"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Moderna 's ( MRNA -20.49%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $38.5 which represents a slight increase of $2.61 or 7.27% from the prior close of $35.89. The stock opened at $36.35 and touched a low ...

Moderna Inc (NASDAQ:MRNA) stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro. On ...

Key Takeaways U.S. equities rose at midday Tuesday on optimism that the new tariffs threatened by President Trump won't be as ...

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its ...

Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.

CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...